Pfizer announced that CFO Dave Denton will step down Aug. 15; Cecile Guegan will serve as interim CFO while the company launches a search for a successor. The move follows several major deals that reshaped Pfizer’s balance sheet.

A Rutgers genetic survey found many city mice carry mutations that blunt commonly used poisons, complicating pest control in Brooklyn.

A New York‑led coalition of state attorneys general served OpenAI with a sweeping subpoena seeking memos on advertising, retention, data and child and senior safety as the company confirms a confidential IPO filing.

Federal prosecutors say LangInnov settled after allegedly performing SBIR‑funded R&D overseas, a possible breach of NSF rules. The U.S. Attorney’s office framed the move as enforcement of domestic R&D requirements.

Long Island scientists are growing patient 'avatars' — organoids — to test dozens of drug combinations. Early trials show promise but wider validation and faster methods are still needed.

Albany approved S9051 this week to bar AI chatbot features that can harm or manipulate kids; the move was driven by parents testimony and advocacy groups.

Flourish surfaced from stealth with $500M and a $2.5B valuation, backed by Bezos and top VCs, promising a low‑power 'Cortex AI' that blends neuroscience and machine learning.

Columbia researchers report precise base edits in early human embryos, targeting PCSK9 and HBG. Experts warn mosaicism and long‑term safety risks remain.

Justice Department files show Jeffrey Epstein deposited sperm with California Cryobank and signed a 2016 contract leaving the samples to his estate; the material’s whereabouts remain unclear.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

Updated CHORD trial numbers presented in Seoul suggest most children with otoferlin‑related deafness gained meaningful hearing after Otarmeni treatment. The therapy was FDA‑cleared in April.

Early trial data show amivantamab shrank—and in some patients erased—tumors in treatment‑resistant head and neck cancer, with results set for ASCO on Sunday. Investigators call the responses striking but preliminary.

Columbia researchers identify SIRT1 as a driver of treatment‑resistant neuroendocrine prostate cancer and show blocking it halts tumors in mice.